000 | 02812nam a22004695i 4500 | ||
---|---|---|---|
001 | 978-3-642-39968-8 | ||
003 | DE-He213 | ||
005 | 20140220082520.0 | ||
007 | cr nn 008mamaa | ||
008 | 131004s2014 gw | s |||| 0|eng d | ||
020 |
_a9783642399688 _9978-3-642-39968-8 |
||
024 | 7 |
_a10.1007/978-3-642-39968-8 _2doi |
|
050 | 4 | _aQR46 | |
072 | 7 |
_aMMFM _2bicssc |
|
072 | 7 |
_aMED052000 _2bisacsh |
|
082 | 0 | 4 |
_a616.9041 _223 |
100 | 1 |
_aMarinelli, Flavia. _eeditor. |
|
245 | 1 | 0 |
_aAntimicrobials _h[electronic resource] : _bNew and Old Molecules in the Fight Against Multi-resistant Bacteria / _cedited by Flavia Marinelli, Olga Genilloud. |
264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg : _bImprint: Springer, _c2014. |
|
300 |
_aVIII, 364 p. 71 illus., 10 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
520 | _aReports on the emergence and prevalence of resistant bacterial infections in hospitals and communities raise concerns that we may soon no longer be able to rely on antibiotics as a way to control infectious diseases. Effective medical care would require the constant introduction of novel antibiotics to keep up in the “arms race” with resistant pathogens. This book closely examines the latest developments in the field of antibacterial research and development. It starts with an overview of the growing prevalence of resistant Gram-positive and Gram-negative pathogens, including their various resistance mechanisms, prevalence, risk factors and therapeutic options. The focus then shifts to a comprehensive description of all major chemical classes with antibacterial properties, their chemistry, mode of action, and the generation of analogs; information that provides the basis for the design of improved molecules to defeat microbial infections and combat the emerging resistances. In closing, recently developed compounds already in clinical use, those in preclinical or first clinical studies, and a number of promising targets to be exploited in the discovery stage are discussed. | ||
650 | 0 | _aMedicine. | |
650 | 0 | _aMicrobiology. | |
650 | 0 | _aDrug interactions. | |
650 | 0 | _aEmerging infectious diseases. | |
650 | 1 | 4 | _aBiomedicine. |
650 | 2 | 4 | _aMedical Microbiology. |
650 | 2 | 4 | _aDrug Resistance. |
650 | 2 | 4 | _aInfectious Diseases. |
650 | 2 | 4 | _aApplied Microbiology. |
700 | 1 |
_aGenilloud, Olga. _eeditor. |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer eBooks | |
776 | 0 | 8 |
_iPrinted edition: _z9783642399671 |
856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-642-39968-8 |
912 | _aZDB-2-SBL | ||
999 |
_c93377 _d93377 |